Related Experiment Video

Updated: Jan 5, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Temsirolimus acts as additive with bendamustine in aggressive lymphoma

Anna-Katharina Zoellner1,2, Tobias Weiglein3,4, Grit Hutter4

  • 1Department of Internal Medicine III, University Hospital Munich-Großhadern, Marchioninistr. 15, 81377, Munich, Germany. anna.zoellner@med.lmu.de.

Annals of Hematology
|December 15, 2015
PubMed

Insights

Temsirolimus combined with bendamustine and rituximab achieved a complete remission in a lymphoma patient. In vitro studies showed this combination effectively reduces cancer cell growth by inhibiting cell cycle and inducing apoptosis.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and survival, and frequently dysregulated in cancers.
  • Temsirolimus targets the mTOR pathway, while bendamustine shows efficacy in lymphomas like mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL).

Observation:

  • A case report details a pretreated male patient achieving complete remission (CR) with a combination of temsirolimus, bendamustine, and rituximab.
  • In vitro experiments were conducted on MCL and diffuse large B-cell lymphoma (DLBCL) cell lines.

Findings:

  • The combination therapy of temsirolimus, bendamustine, and rituximab resulted in a CR in the patient.
  • In vitro data demonstrated additive and synergistic efficacy of temsirolimus with bendamustine in reducing MCL and DLBCL cell growth.
  • Mechanistic studies revealed cell cycle inhibition and apoptosis induction as underlying factors for the observed additive effects.

Implications:

  • This combination therapy shows promise for treating relapsed or refractory lymphomas.
  • The findings support further investigation into temsirolimus and bendamustine combinations for hematological malignancies.
  • Understanding the mechanisms of action can guide future therapeutic strategies in lymphoma treatment.
Keywords:
BendamustineDLBCLMCLTemsirolimus

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K
Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs08:13

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

19.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
432